Kura Oncology KURA Commercialization Services — Contract With Customer Liability Noncurrent
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
As of March 31, 2026, the remaining unrecognized consideration allocated to the development services for monotherapy was $27.0 million and to the development services in combination with other therapies was $161.7 million. As of March 31, 2026, $275.7 million of consideration allocated to commercialization services and profit and loss sharing payments received or expected to be received, was constrained and included in contract liabilities, of which $2.0 million was classified as current, and $273.7 million was classified as long-term.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's commercialization services — contract with customer liability noncurrent?
- Kura Oncology (KURA) reported commercialization services — contract with customer liability noncurrent of $273.7M in Q1 2026.
- What does commercialization services — contract with customer liability noncurrent mean?
- Represents the portion of deferred revenue from commercialization services that is expected to be recognized as revenue beyond the next twelve months. This reflects long-term contractual obligations where payment has been received or is due before the services are fully performed. It indicates the scale of multi-year commercial partnerships.
Ask your AI about Kura Oncology's commercialization services — contract with customer liability noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
